Subsequent Events	12 Months Ended
Dec. 31, 2024
Subsequent Events [Abstract]
Subsequent Events	18. Subsequent Events. On January 8, 2025, the Company announced that it and its licensor, SERB have entered into a Settlement Agreement with Teva. This agreement resolves the patent litigation brought by the Company and SERB in response to Teva’s ANDA seeking approval to market a generic version of FIRDAPSE® (amifampridine) 10 mg tablets prior to the expiration of the applicable patents. Pursuant to the terms of the settlement agreement, Teva has agreed not to market its generic version of FIRDAPSE® in the U.S. any earlier than February 25, 2035, if approved by the U.S. Food and Drug Administration, unless certain limited circumstances customarily included in these types of settlements occur. In accordance with the Agreement, the Company/SERB and Teva have terminated all ongoing patent litigation between them that is currently pending in the U.S. District Court for the District of New Jersey. The pending FIRDAPSE® patent litigation against the remaining defendants, Hetero (for all of FIRDAPSE®’s Orange Book-listed patents) and Lupin (only for Catalyst’s FIRDAPSE® patent expiring in 2037) is ongoing, and there can be no assurance whether such ongoing patent litigation will allow a generic version of FIRDAPSE® to be marketed in the U.S. prior to February 25, 2035. On January 17, 2025, Charles B. O’Keeffe, an independent member of the Board of Directors (Board) of the Company, advised the Company of his decision to not stand for reelection at the 2025 annual meeting of the Company’s stockholders. Mr. O’Keeffe will continue to serve as a member of the Board until the 2025 annual meeting, when his current term will expire. Mr. O’Keeffe has been a member of the Board since December 2004 and currently serves as the Board’s Lead Independent Director. Mr. O’Keeffe’s intention to retire from the Board was not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies, or practices. On January 21, 2025, the Company reported that its sub-licensee in Japan, DyDo, has launched FIRDAPSE® Tablets 10 mg in Japan for the indication of improving muscle weakness in patients living with LEMS. On February 13, 2025, Gregg Russo was promoted from VP, Head of Human Resources to Chief Human Resources Officer.

Subsequent Events

12 Months Ended

Dec. 31, 2024

18.

Subsequent Events.

On January 8, 2025, the Company announced that it and its licensor, SERB have entered into a Settlement Agreement with Teva. This agreement resolves the patent litigation brought by the Company and SERB in response to Teva’s ANDA seeking approval to market a generic version of FIRDAPSE® (amifampridine) 10 mg tablets prior to the expiration of the applicable patents.

Pursuant to the terms of the settlement agreement, Teva has agreed not to market its generic version of FIRDAPSE® in the U.S. any earlier than February 25, 2035, if approved by the U.S. Food and Drug Administration, unless certain limited circumstances customarily included in these types of settlements occur. In accordance with the Agreement, the Company/SERB and Teva have terminated all ongoing patent litigation between them that is currently pending in the U.S. District Court for the District of New Jersey. The pending FIRDAPSE® patent litigation against the remaining defendants, Hetero (for all of FIRDAPSE®’s Orange Book-listed patents) and Lupin (only for Catalyst’s FIRDAPSE® patent expiring in 2037) is ongoing, and there can be no assurance whether such ongoing patent litigation will allow a generic version of FIRDAPSE® to be marketed in the U.S. prior to February 25, 2035.

On January 17, 2025, Charles B. O’Keeffe, an independent member of the Board of Directors (Board) of the Company, advised the Company of his decision to not stand for reelection at the 2025 annual meeting of the Company’s stockholders. Mr. O’Keeffe will continue to serve as a member of the Board until the 2025 annual meeting, when his current term will expire. Mr. O’Keeffe has been a member of the Board since December 2004 and currently serves as the Board’s Lead Independent Director. Mr. O’Keeffe’s intention to retire from the Board was not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies, or practices.

On January 21, 2025, the Company reported that its sub-licensee in Japan, DyDo, has launched FIRDAPSE® Tablets 10 mg in Japan for the indication of improving muscle weakness in patients living with LEMS.

On February 13, 2025, Gregg Russo was promoted from VP, Head of Human Resources to Chief Human Resources Officer.